Accelerate Diagnostics (AXDX) Stock Price

Accelerate Diagnostics Price

NASDAQ·CLOSED
0.01
​
Market closed

Over the last 19 years Accelerate Diagnostics grew revenue by 18.0% annually, reaching 11.70 M USD. For Accelerate Diagnostics, the net margin of -427.8% is up versus -700.5% a few years ago.

Accelerate Diagnostics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics business model & stock analysis

Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections.

Frequently asked questions about Accelerate Diagnostics

7 analysts currently rate the Accelerate Diagnostics stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Accelerate Diagnostics to generate revenue of 22.40 M USD and earnings per share of -0.36 USD.

Converted at the current exchange rate, the Accelerate Diagnostics share trades at 0.01 EUR (0.01 USD).

The Accelerate Diagnostics share (AXDX) is listed on 5 stock exchanges, including: NASDAQ (AXDX), London (0H8E.L), SIX (Zürich) (1A8.SW), Frankfurt (1A8.F), Düsseldorf (1A8.DU).

The expected revenue of Accelerate Diagnostics is 22.40 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Accelerate Diagnostics is -8.39 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Accelerate Diagnostics is currently -0.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Accelerate Diagnostics stock.

The price-to-sales ratio (P/S) of Accelerate Diagnostics is currently 0.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Accelerate Diagnostics stock.

The Eulerpool Quality Score for Accelerate Diagnostics is 5/10.

The ISIN of Accelerate Diagnostics is US00430H2013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Accelerate Diagnostics is A1KA68. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Accelerate Diagnostics is AXDX. The ticker symbol is used to trade Accelerate Diagnostics shares on the stock exchange.

Fair ValueTerminal
0.01 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
109,327.10 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 27, 1993
ISIN
US00430H2013
Cusip
00430H102
Sedol
B8QZWL9
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.01
P/Ee 2026
-0.03
P/S
P/Se
0.02
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-673.28 %
Last updated Nov 10, 2026, 1:12 AM

Accelerate Diagnostics Ticker

DÜSSELDORF · 1A8.DUFRANKFURT · 1A8.FLONDON · 0H8E.LNASDAQ · AXDXSIX · 1A8.SW

All fundamentals and in-depth analysis of Accelerate Diagnostics

Our stock analysis for Accelerate Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Accelerate Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.